Site Editor



ASCO 2023: Patient-Reported Outcomes With Adjuvant Atezolizumab and Bevacizumab in Hepatocellular Cancer

By: Joshua Swore, PhD
Posted: Monday, June 5, 2023

Patient-reported results from the phase III IMbrave050 trial, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4002), demonstrated similar overall health-related quality of life and functioning with adjuvant atezolizumab plus bevacizumab compared with active surveillance in patients at high risk of recurrence of hepatocellular carcinoma. In a previous report from this trial, the combination therapy yielded a statistically significant improvement in recurrence-free survival versus active surveillance in this patient population. The quality-of-life results were presented by Masatoshi Kudo, MD, PhD, of Kindai University Hospital, Osaka, Japan, and colleagues.

Patients enrolled into the IMbrave050 study were diagnosed with hepatocellular carcinoma and at high risk of recurrence after resection or ablation. The study placed 334 patients into two arms: Arm A included treatment with atezolizumab plus bevacizumab for 1 year. Arm B included active surveillance with the option to cross over and be treated with atezolizumab plus bevacizumab after recurrence.

In this current trial update, the investigators used the IL42-European Organisation for the Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ)-C30 to assess global health status/quality of life, physical/emotional role, and social functioning. The questionnaire completion rate for both arms of the study was 93% through the course of treatment or surveillance, respectively. Patients reportedly had a high rating at baseline, with normal changes throughout the treatment regimen. The authors claimed that ratings were similar between the arms because of overlapping confidence intervals. Researchers concluded that the treatment was generally manageable and fit the established safety profiles of treatment drugs and the underlying disease.

Previously, at a median follow-up time of 17.4 months, a median independent review facility determined a recurrence-free survival hazard ratio of 0.72 (95% confidence interval = 0.56–0.93; P = .012). Grade 3 or 4 adverse events occurred in 41% of those in arm A and 13% of those in arm B.

Disclosure: Full disclosures of the study authors are not available.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.